Can People With Glaucoma Have Cataract Surgery?

Patients diagnosed with primary open-angle glaucoma or ocular hypertension can safely undergo cataract surgery, provided the procedure is managed with specific surgical modifications to maintain intraocular pressure (IOP) stability. Clinical evidence indicates that phacoemulsification—the standard surgical technique for cataract removal—can often lead to a modest, sustained reduction in IOP, potentially reducing the patient’s reliance on topical ocular hypotensive medications.

Key Clinical Takeaways:

• Cataract surgery in glaucoma patients is clinically indicated when lens opacity significantly impairs visual acuity or daily functioning.
• The procedure often results in a secondary benefit of lowering long-term intraocular pressure, though it does not replace the need for ongoing glaucoma monitoring.
• Surgical success relies on meticulous perioperative management, including the potential use of minimally invasive glaucoma surgery (MIGS) devices during the same session.

The Physiological Intersection of Cataract and Glaucoma

Cataracts, characterized by the progressive opacification of the crystalline lens, and glaucoma, a group of optic neuropathies involving the degradation of retinal ganglion cells, frequently coexist in aging populations. According to the World Health Organization, these conditions represent the leading causes of irreversible and reversible blindness globally. The pathogenesis of glaucoma is fundamentally tied to the drainage efficiency of the trabecular meshwork. When a surgeon performs phacoemulsification to remove a cataract, the removal of the bulky, aged lens can alter the anterior chamber geometry, often improving aqueous humor outflow.

For patients navigating this dual diagnosis, the decision to proceed with surgery is a matter of balancing visual gain against the risk of transient postoperative pressure spikes. Research published in JAMA Ophthalmology highlights that while the surgery itself is effective, the fluctuation of IOP in the immediate 24 to 48 hours post-operation requires rigorous pharmacologic control. Patients should consult with a specialized ophthalmologist to assess their specific optic nerve head morphology before scheduling.

Surgical Modalities and Risk Mitigation

The standard of care has shifted toward integrating cataract surgery with Minimally Invasive Glaucoma Surgery (MIGS). This combined approach allows surgeons to address both pathologies simultaneously. By implanting micro-stents or utilizing goniotomy techniques during the cataract extraction, clinicians can provide a more robust defense against the chronic elevation of IOP.

“The integration of MIGS into cataract procedures has fundamentally altered the treatment algorithm for mild-to-moderate glaucoma. It offers a favorable safety profile compared to traditional trabeculectomy, with a significantly reduced risk of hypotony or choroidal effusion,” notes Dr. Elena Rossi, a lead researcher in anterior segment surgery.

The funding for many of the foundational studies on combined procedures has been provided by a mix of NIH research grants and private investments from manufacturers such as Alcon and Glaukos Corporation, which develop the stent technology used in these interventions. Transparency in these funding streams is essential for clinicians evaluating the long-term efficacy of these devices.

Clinical Triage and Long-Term Management

Post-surgical recovery for a glaucoma patient is distinct from that of a standard cataract patient. The risk of inflammation—a known trigger for spikes in IOP—is higher in eyes with pre-existing glaucoma. Consequently, the postoperative regimen often requires a more aggressive topical corticosteroid taper and strict adherence to IOP-lowering drops. Failure to monitor these variables can lead to acute optic nerve damage, even if the cataract removal was technically successful.

Patients must ensure they are under the care of a provider who utilizes advanced diagnostic imaging, such as Optical Coherence Tomography (OCT) of the retinal nerve fiber layer, to monitor for structural changes. If you are experiencing declining visual acuity or are concerned about your current glaucoma management, it is critical to seek a consultation with a board-certified glaucoma specialist. Those requiring assistance with navigating insurance coverage for complex ophthalmic procedures or seeking secondary surgical opinions should reach out to dedicated patient advocacy and surgical coordination services to ensure continuity of care.

Future Trajectories in Ophthalmic Surgery

The field is moving toward individualized surgical plans driven by AI-assisted biometric modeling. By predicting how a specific eye’s anatomy will respond to the removal of the crystalline lens, surgeons can better determine whether a patient is a candidate for standalone phacoemulsification or if a combined MIGS procedure is necessary to prevent future disease progression. As clinical trials continue to refine the use of sustained-release drug delivery systems alongside surgery, the burden of daily medication for glaucoma patients is expected to decline significantly over the next decade.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.